Lineage Cell Therapeutics, Inc. (LCTX)

Genentech Licensing Agreement For OpRegen Begins Transformation


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
December 21, 2021
Report ID: 24339
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc.
Healthcare
Biotechnology
Ticker
LCTX
Current Price
$1.5 1.35%
Market Cap
$225.0M
Price Target
Refer to Report
Volume
235.3K
52wk Range
$1.02 - $2.71
Related Research Reports
8/15/2022

OpRegen Collaboration Advances As Pipeline Products Move Toward INDs
OpRegen Collaboration Advances As Pipeline Products Move Toward INDs (LCTX)
5/13/2022

1Q22 Reported With Clinical Program Review
1Q22 Reported With Clinical Program Review (LCTX)
4/26/2022

New Program Added To The Development Pipeline
New Program Added To The Development Pipeline (LCTX)
3/22/2022

New Addition To Product Pipeline in Hearing Loss
New Addition To Product Pipeline in Hearing Loss (LCTX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.